SIETES :: 91969 citas

Resultados de la búsqueda por NOTIFICACIÓN VOLUNTARIA REFINAR BÚSQUEDA

1.

Gedeborg R, Svennblad B, Holm L, Sjögren H, Bardage C, Personne M, Sjöberg G, Feltelius N, Zethelius B. Increased availability of paracetamol in Sweden and incidence of paracetamol poisoning: using laboratory data to increase validity of a population-based registry study. Pharmacoepidemiol Drug Saf 2017;26:518-27. [Ref.ID 101958]

2.

Pierson-Marchandise M, Gras V, Moragny J, Micallef J, Gaboriau L, Picard S, Choukroun G, Masmoudi K, Liabeuf S, the French National Network of Pharmacovigilance Centres. The drugs that mostly frequently induce acute kidney injury: a case-noncase study of a pharmacovigilance database. Br J Clin Pharmacol 2017;83:1341-9. [Ref.ID 101945]

3.

Anónimo. Se recomienda no iniciar nuevos tratamientos con ?Monoferro® (hierro-isomaltósido) debido al riesgo de reacciones graves de hipersensibilidad. Agencia Española de Medicamentos y Productos Sanitarios (AEMPS) 2017:1-2. [Ref.ID 101915]

4.

Coste J. Diverging approaches of pharmacovigilance and pharmacoepidemiology to assessing drug safety: epistemological and ethical implications. Pharmacoepidemiol Drug Saf 2017;26:600-2. [Ref.ID 101606]

5.

Anónimo. Finasteride: rare reports of depression and suicidal thoughts. Drug Safety Update 2017;10:2-3. [Ref.ID 101600]

6.

Plessis L, Gómez A, García N, Cereza G, Figueras A. Lack of essential information in spontaneous reports of adverse drug reactions in Catalonia - a restraint to the potentiality for signal detection. Eur J Clin Pharmacol 2017;73:3 de marzo. [Ref.ID 101453]

7.

Anónimo. AINS: infections des tissus mous et complications suppuratives de pneumopathies bactériennes. Prescrire 2017;37:109. [Ref.ID 101429]

8.

Goldblatt C, Khumra S, Booth J, Urbancic K, Grayson ML, Trubiano JA. Poor reporting and documentation in drug-associated Stevens-Johnson syndrome and toxic epidermal necrolysis – Lessons for medication safety. Br J Clin Pharmacol 2017;83:224-6. [Ref.ID 101406]

9.

Agah E, Habibi A, Naderi H, Tafakhori A. Metronidazole-induced neurotoxicity presenting with sudden bilateral hearing loss, encephalopathy, and cerebellar dysfunction. Eur J Clin Pharmacol 2017;73:249-50. [Ref.ID 101405]

10.

Tricco AC, Zarin W, Lillie E, Pham B, Straus SE. Utility of social media and crowd-sourced data for pharmacovigilance: a scoping review protocol. BMJ Open 2017;7:e013474. [Ref.ID 101354]

11.

Sorigue M, Sarrate E, Orna E. Hemorragia intracraneal durante el tratamiento con apixabán. Med Clin (Barc) 2017;148:47-8. [Ref.ID 101342]

12.

Rodrigo-Troyano A, Mediavilla MM, Garin N, Güell R. Insuficiencia cardíaca secundaria a tratamiento con itraconazol. Med Clin (Barc) 2017;148:69-70. [Ref.ID 101341]

13.

Hawcutt DB, Russell N-J, Maqsood H, Kouranloo K, Gomberg S, Waitt C, Sharp A, Riordan A, Turner MA. Spontaneous adverse drug reaction reports for neonates and infants in the UK 2001–2010: content and utility analysis . Br J Clin Pharmacol 2016;82:1601-12. [Ref.ID 101026]

14.

Aguirre C, García M. Evaluación de la causalidad en las comunicaciones de reacciones adversas a medicamentos. Algoritmo del Sistema Español de Farmacovigilancia. Med Clin (Barc) 2016;147:461-4. [Ref.ID 100932]

15.

Anónimo. Aripiprazole: pulsions pathologiques. Prescrire 2016;36:667. [Ref.ID 100823]

16.

Anónimo. Topiramate, zonisamide: panilopsies. Prescrire 2016;36:666. [Ref.ID 100822]

17.

Anónimo. Aflibercept: ostéonécroses de mâchoire. Prescrire 2016;36:666. [Ref.ID 100821]

18.

Anónimo. Direct-acting antivirals for hepatitis C: drug safety communication - Risk of hepatitis B reactivating. FDA U.S. Food and Drug Administration 2016:4 de octubre. [Ref.ID 100780]

19.

Ekhart C, de Jong L, Gross-Martirosyan L, van Hunsel F. Muscle rupture associated with statin use. Br J Clin Pharmacol 2016;82:473-7. [Ref.ID 100689]

20.

Moore TJ, Furberg CD, Mattison DR, Cohen MR. Completeness of serious adverse drug event reports received by the US Food and Drug Administration in 2014. Pharmacoepidemiol Drug Saf 2016;25:713-8. [Ref.ID 100396]